Want help reviewing this study?
Study ID: NCT07288320. We help you review the study, but cannot decide medical eligibility.
RecruitingNCT07288320
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolarity type I With Current Mania
A short description of this study’s research objective has not yet been verified.
Medication studyAges 18–65United States
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Little Rock, United States · Cerritos, United States and 9 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: December 24, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 150
- Sponsor
- Neurocrine Biosciences
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07288320
- Official title
- A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder Who Are Currently Experiencing a Manic Episode or Manic Episode With Mixed Features, With or Without Psychotic Symptoms, and Warrant Inpatient Hospitalization
Recruitment & locations
RecruitingLittle Rock · Cerritos · Garden Grove
8 more locations
- San Diego
- Hollywood
- Atlanta
- Gaithersburg
- Marlton
- Staten Island
- Austin
- Houston
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Neurocrine Biosciences, a biotech company.
Does this study involve medication?
Yes. The study involves medication, including NBI-1117568 and Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
RecruitingNCT07286175
Brenipatide in adults with Bipolarity (RENEW-Bipolar-1)
The registry lists this study as recruiting. Study locations are listed in the United States, in Argentina, in Brazil, ... Confirm recruitment at each site. It is testing brenipatide for Bipolarity.
RecruitingNCT06696755
Adverse Events and Change for Bipolarity
The registry lists this study as recruiting. Study locations are listed in the United States. Confirm recruitment at each site. It is testing adverse Events and Change for Bipolarity.
RecruitingNCT04777357
Change for depression
The registry lists this study as recruiting. Study locations are listed in the United States and in Russia. Confirm recruitment at each site. It is testing change for depression.